Recent large-scale genetic studies have allowed for the first glimpse of the effects of common genetic variability in dementia with Lewy bodies (DLB), identifying risk variants with appreciable effect sizes. However, it is currently well established that a substantial portion of the genetic heritable component of complex traits is not captured by genome-wide significant SNPs. To overcome this issue, we have estimated the proportion of phenotypic variance explained by genetic variability (SNP heritability) in DLB using a method that is unbiased by allele frequency or linkage disequilibrium properties of the underlying variants. This shows that the heritability of DLB is nearly twice as high as previous estimates based on common variants only (31% vs 59.9%). We also determine the amount of phenotypic variance in DLB that can be explained by recent polygenic risk scores from either Parkinson's disease (PD) or Alzheimer's disease (AD), and show that, despite being highly significant, they explain a low amount of variance. Additionally, to identify pleiotropic events that might improve our understanding of the disease, we performed genetic correlation analyses of DLB with over 200 diseases and biomedically relevant traits. Our data shows that DLB has a positive correlation with education phenotypes, which is opposite to what occurs in AD. Overall, our data suggests that novel genetic risk factors for DLB should be identified by larger GWAS and these are likely to be independent from known AD and PD risk variants.
Introduction
Recent studies have highlighted the role of genetics in the common, but often underappreciated, form of dementia that is dementia with Lewy bodies (DLB). Associations with GBA, APOE and SNCA have all been reproducibly reported by independent groups (1) (2) (3) , and a recent genomewide association study (GWAS) identified several risk and candidate variants associated with the disease (4). However, GWAS significant single nucleotide polymorphisms (SNPs) often explain only a small proportion of the total heritability estimated (usually from family-based studies) for a given trait, which results in the 'missing heritability' issue (5) . One of the possible explanations for this issue is that all common SNPs, regardless of their association p-value, contribute to the heritability of complex traits (6) (7) (8) . However, given that each individual associated marker explains only a small proportion of the genetic variation with little predictive power, methods have been developed to test disorder prediction by summarizing variation across many loci (regardless of association p-values) into quantitative scores. One such approach is the generation of polygenic risk scores (PRSs). PRSs have been successfully applied to Parkinson's (PD) (9) and Alzheimer's diseases (AD) (10) and their usefulness will continue to increase as discovery datasets are augmented.
A separate, but related, concept is that of genetic correlation of traits.
Here, what is estimated is the genetic covariance between traits that is tagged by common genome-wide SNPs (11) . This allows us to identify pleiotropic effects between traits that might be unrelated by any other measurement. We have performed a preliminary study of genetic correlation between DLB and both PD and AD (12) , however performing similar analyses with other (even apparently unrelated) traits might provide novel insights for the underlying pathobiology of disease and perhaps for treatments across diseases.
The phenotypic variance of most complex human traits combines the genetic with the environmental variance (13) . While the effects of the environment are difficult to ascertain given their complexity and lack of adequate measurements, we are able to determine the genetic variance more accurately. Classically, genetic variance has been partitioned into sources of variation due to additive, dominance and epistatic effects.
Additive genetic variance (h 2 SNP) relates to an allele's independent effect on a phenotype; dominance variance (δ 2 SNP) refers to the effect on a phenotype caused by interactions between alternative alleles at a specific locus; epistatic variance refers to the interaction between different alleles in different loci. Most available cohorts for studies of human biology and disease are still underpowered to identify epistatic events, however, additive and dominance variance can be estimated from standard genome-wide genotyping data (14) .
Here, using data from the first GWAS in DLB that included haplotype reference consortium (HRC)-imputed genotypes (15), we have estimated the total heritability of this disease. We used a method (GCTA-LDMS) that is unbiased regardless of the minor allele frequency (MAF) and linkage disequilibrium (LD) properties of variants and thus greatly improves on previous estimates (16) . Since it has been suggested that heritability estimates may be inflated by non-additive variation (17), we have also estimated the dominance genetic variation in DLB.
Additionally, to measure the proportion of variance explained by PRSs from PD and AD in a large DLB cohort, we measured the ability of PRS to discriminate case from control subjects. Lastly, to attempt to derive novel biological insights from unrelated traits, we have performed pairwise genetic correlation analysis of DLB with 235 phenotypes, including cognitive, anthropometric and education traits.
Results

Quantifying the genetic heritability of DLB
We applied the GREML-LDMS approach to estimate the proportion of phenotypic variance explained by the HRC-imputed variants for DLB.
Results from this approach showed that imputed variants with R 2 greater than or equal to 0.3 and frequency above 0.1% explained 59.9% (s.e.= 2.1%; p=6.8x10 
Polygenic Prediction of Case-Control Status
We applied the PRSs derived from AD and PD data to determine if these would discriminate between DLB and controls. The AD score explained 1.33% of the variance (Nagelkerke's pseudo-R 2 ) and was highly significant (p = 5.8x10 -31 ). Performing the same analysis while excluding the APOE locus brought the estimate down to 0.14%, while reaching only nominal significance. Using the PD polygenic risk score, we obtained an estimate of 0.37% of the variance in DLB being explained by that score, a result that was also significant (p=6.4x10 -10 ). Interestingly, removing the GBA locus resulted in only a small reduction in the variance explained by the PD PRS (0.36%; p=1.23x10 -9 ) at the best p-value threshold.
The bar plots of DLB variance explained by the AD and PD polygenic risk scores are presented in Figure 2 . As expected given these results, DLB cases had on average higher polygenic risk scores than control subjects for both PD and AD ( Figure 3 ).
Unbiased genetic correlation
To test whether DLB has a shared genetic etiology with any of 235 other diseases or biomedical relevant traits, we used LD score regression as implemented in LDHub (http://ldsc.broadinstitute.org/ldhub/). This method estimates the degree to which genetic risk factors are shared between pairs of diseases or traits, although it should be noted that it does not inform regarding how this shared genetic etiology arises. We selected the correlations with a p-value <0.01 in DLB and tested these in AD and PD ( Figure 4 ). The most significant correlation identified between DLB and each of the 235 tested traits was with "Years of schooling" (18) sizes will allow us to identify novel loci involved in conferring risk for disease without the need for large-scale whole-genome sequencing.
One of the explanations for the common issue of "missing heritability" is that non-additive heritability (such as dominance variance or epistatic variance) represents a substantial component of a trait's total heritable genetic component. Our results suggest that dominance variance has a negligible effect on the genetic heritability of DLB, in line with findings from 79 unrelated traits (14) . However, we cannot exclude that epistatic variance plays a role in DLB, given that our cohort is underpowered to detect epistatic events.
Recently, there has been growing interest in the use of PRSs as a way to perform risk prediction in various diseases and these have successfully been applied to AD (10) and PD (9) . To determine how much of the phenotypic variance in our DLB cohort can be caused by AD and PD known genetic risk factors, we used PRSs from recent GWAS from each of these diseases. In both cases scores were predictive of case-control status, although explaining only relatively small proportions of variance (0.37-1.33%). In AD, excluding the APOE locus greatly reduced the amount of variance explained in DLB (0.14%), which is in accordance with the strong effect that locus has in the risk of both diseases (4, 22) .
Conversely, excluding the GBA locus in PD had only a modest effect, which likely results from the lower frequency in the general population of the variants that comprised this signal compared to APOE. Since the amount of variance explained by each of the PRS is relatively small, this adds to the growing body of evidence that suggests that, genetically, DLB is a unique condition and not simply a mix of PD and AD risk factors.
These data also confirm the polygenic nature of DLB as well as quantify the amount of variance that polygenic risk from each of those diseases accounts for in DLB.
Given the large number of pleiotropic events that are being identified for a variety of diseases and traits (23, 24) , finding correlated conditions and DLB oxidative stress may be involved in the neurodegenerative processes, while in PD it may be more akin to a consequence. We note several limitations in our study. First, the DLB dataset, despite being the largest to date, is relatively small when compared to other recently published GWAS. This has implications in the statistical power to make novel findings and is reflected in the standard errors of the analyses performed. We are underpowered to detect rare variants and certainly rare variants with small effect sizes. Second, we are unable to provide definitive biological mechanisms underlying the genetic correlations identified. This means that it is possible that for some of the correlations observed, what we are seeing are proxy effects and not direct correlations. Lastly, this study focused on individuals of European/North American descent. It is likely that studies of populations of different ancestries will reveal not only novel loci, but perhaps also novel pleiotropic effects, which could improve our understanding of the pathobiology of DLB.
In summary, we provide updated estimates of the genetic heritability of DLB and show that dominance variance is not a substantial part of the heritability of this disease. We quantify the amount of phenotypic variance in DLB that can be attributed to PD and AD polygenic risk scores and show that this is relatively small. Lastly, we estimate genetic correlations between DLB and over 200 diseases and medically relevant traits, shedding light into the complex relationship between DLB and both PD and AD.
Materials and Methods
Sample description
The DLB dataset was previously published (4) 
DLB heritability estimates
We used the GCTA-LDMS method to estimate heritability based on imputed data (16, 33) Lastly, we performed restricted maximum likelihood (REML) analysis using the multiple GRMs.
DLB dominance variance estimates
To estimate the dominance GRM between pairs of individuals, we used genome-wide imputed SNPs as implemented in GCTA-GREMLd (14) .
This method calculates the additive and dominance GRMs and fits both GRMs in a mixed linear model to estimate additive and dominance variance simultaneously.
PRS analyses
Determining the polygenic risk of a given phenotype and applying it to another trait is an approach that allows to determine shared genetic aetiology between traits. We calculated PRSs on the base phenotypes (PD and AD), using GWAS summary statistics, and used these as predictors of the target phenotype (DLB) in a regression test. To construct and apply the PRSs we used PRSice v2.1 (34) . We performed clumping on the target data by retaining the SNP with the smallest p-value from each LD block (excluding SNPs with r2 > 0.1 in 250kb windows). Each allele was weighted by its effect-size as estimated in the respective study (for PD and AD). Association of PRSs with case-control status was performed with logistic regression, and Nagelkerke's pseudo-R 2 was calculated to measure the proportion of variance explained.
Genetic correlation analysis
To estimate the genetic correlation between DLB and other complex traits and diseases, we used a method based on LD score regression and implemented in the online web utility LDHub v1.9.0 (27, 35) . The LD score regression method uses summary statistics from the DLB GWAS and the other available traits, calculates the cross-product of test statistics at each SNP, and then regresses the cross-product on the LD score. After identifying the most significant correlations for DLB (p<0.01), we estimated the correlation of those traits with PD and AD.
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